Parkinson’s disease to surge to 3.15 million worldwide by 2033, finds report

Parkinson’s disease, a brain condition that causes problems with movement, mental health, sleep, pain and other health issues, is growing rapidly. In 2023, the number of cases related to

Parkinson’s disease

was 2.16 million and this is expected to grow up to 3.15 million in 2033.
The report by GlobalData, a data and analytics company, showed the rise in prevalence of diagnosed cases of the progressive brain disorder will specifically be seen in the seven major countries — the US, France, Germany, Italy, Spain, the UK, and Japan, news agency IANS reported.
“In 2023, adults aged 60 and older accounted for over 90 per cent of diagnosed prevalent cases of PD, while adults ages 18-39 made up less than 1 per cent. This age distribution aligns with findings showing higher PD prevalence among older populations,” said Rahul N Ravi, Senior Epidemiologist at GlobalData.

Parkinson’s Disease gets worse over time

Quality of life can be significantly impacted after the onset of Parkinson’s disease, as it limits independence and social interactions. Feelings of frustration or isolation are common due to the progressive nature of the disease. However, treatment options, including medications, physiotherapy, occupational therapy, and emotional support, can help manage symptoms and improve day-to-day functioning.
Parkinson’s disease affects movement. After diagnosis, individuals experience symptoms that can significantly impact their quality of life. These symptoms are often categorized into motor and non-motor.

Motor symptoms include tremors, rigidity, slowness of movement (bradykinesia), and postural instability, leading to challenges with walking, balance, and coordination. Over time, these symptoms may make routine tasks, such as eating, dressing, or writing, more difficult. Speech and facial expressions may also be affected, reducing ease of communication.
Non-motor symptoms are equally challenging, including fatigue, sleep disturbances, depression, anxiety, and cognitive changes like memory loss or difficulty concentrating. Digestive issues, loss of smell, and chronic pain are common, further reducing comfort and well-being.
“PD is among the most common chronic, progressive

neurodegenerative disorders

affecting the elderly population. As PD predominantly impacts older adults, countries with growing ageing populations must develop strategies to address the healthcare needs of individuals with PD,” Ravi said.
He added that in the coming 10 years, the seven countries with the highest risk are expected to be crucial for PD treatment due to their ageing populations.